AGC Biologics
AGC Biologics is a global CDMO providing development and manufacturing services for protein-based biologics, cell and gene therapies, and messenger RNA.
Last updated September 15, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
AGC Biologics is a global contract development and manufacturing organization (CDMO) headquartered in Seattle, Washington, USA. It provides pharmaceutical development and manufacturing services for protein-based biologics, cell and gene therapies, and messenger RNA, with multiple sites and teams of scientists across three continents. The company specializes in mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cell therapies, offering services from process development and analytical development to cGMP manufacturing, quality control and quality assurance, and process validation. AGC Biologics is part of AGC Inc., a global business conglomerate with over 186 companies and net sales of over $13 billion during FY2025.
History
AGC Biologics is a global CDMO headquartered in Seattle, Washington, USA. In December 2016, CMC Biologics announced that all of its shares were being acquired, and AGC Biologics is now part of AGC Inc., a global business conglomerate with over 186 companies and net sales of over $13 billion during FY2025.
Products and positioning
A global CDMO providing development and manufacturing services for protein-based biologics and advanced therapies.
AGCellerate™ mAbs
A service offering guaranteed speed and product quantity for monoclonal antibody drug substance, getting from DNA transfection to clinical-ready GMP drug substance in only 11 months.
AGCellerate™ LVV
A lentiviral vector service using a proven plug-and-play method to deliver LVV product in a rapid timeline, easing the path to Phase I in 9 months.
CHEF1™
A proprietary commercial cell line that has produced 5 commercial products and 54 molecules at various stages of clinical development.
Recent events
AGC Biologics wins 2021 Transatlantic Award[5]
AGC Biologics won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy for its investments in the Italian biopharmaceutical industry. The award was presented at a gala dinner on December 2 in Milan.
AGC Biologics expands Novavax partnership for U.S. adjuvant supply[6]
Reported:
AGC Biologics announced an expanded partnership with Novavax, adding production of the Matrix-M adjuvant for Novavax’s COVID-19 vaccine at AGC Biologics’ Seattle facility to support U.S. supply.
AGC Biologics announces planned acquisition of MolMed[7]
Reported:
AGC Biologics announced that it planned to acquire most of the share capital of Molecular Medicine S.p.A. (MolMed) on July 31, 2020.
- Unconfirmed
AGC Biologics acquires Colorado manufacturing facility[8]
Reported:
AGC Biologics announced that it had acquired a commercial manufacturing facility in Boulder, Colorado, previously owned by AstraZeneca.
AGC Biologics announces purchase of Colorado manufacturing facility[9]
Reported:
AGC Biologics announced the purchase of a commercial manufacturing facility in Boulder, Colorado, formerly owned by AstraZeneca. The facility is expected to begin full-scale operations and manufacturing by April 2021.
AGC Biologics and AdaptVac announce vaccine-development partnership[10]
Reported:
AGC Biologics announced a partnership with AdaptVac to jointly develop and manufacture a COVID-19 vaccine.
AGC Biologics announces Seattle and Copenhagen capacity expansions[11]
Reported:
AGC Inc. announced plans to add a 500-liter mammalian-cell bioreactor at AGC Biologics’ Seattle facility and install a purification line and additional analytic labs at its Copenhagen facility. Operations were scheduled to begin in April 2020 in the US and October in Europe.
AGC Biologics appoints Copenhagen facility director/general manager[12]
Reported:
AGC Biologics announced the appointment of Jeffery D. Mowery as director/general manager of its Copenhagen facility.
Sources15 sources
- 1Contract Development Manufacturing (CDMO) | Biologics and Cell & Gene Therapies: AGC Biologicsagcbio.com
- 2About Us | CDMO | AGC Biologicsagcbio.com
- 3AGCellerate | DNA to IND Drug Substance Services | AGC Biologicsagcbio.com
- 4AGC Biologics Services | CDMOagcbio.com
- 5AGC Biologics获得2021年跨大西洋奖medindia.net
- 6AGC Biologics扩大与Novavax的合作，为美国供应佐剂iltempo.it
- 7AGC Biologics宣布计划收购MolMedprnasia.com
- 8AGC Biologics收购科罗拉多州制造设施prnasia.com
- 9AGC Biologics宣布收购科罗拉多州制造设施prnewswire.com
- 10AGC Biologics与AdaptVac宣布疫苗开发合作finanznachrichten.de
- 11AGC Biologics宣布扩建西雅图和哥本哈根产能chemengonline.com
- 12AGC Biologics任命哥本哈根设施主任/总经理prnasia.com
- 13AGC Biologics任命博尔德厂负责人prnasia.com
- 14AGC Biologics任命米兰工厂总经理prnasia.com
- 15AGC Biologics为日本千叶运营部门任命新的主任/总经理prnasia.com
Cite this profile: Cite the canonical profile. /brand-wiki/agc-biologics · Editorial policy · How profiles are compiled